Axogen, Inc. announced preliminary unaudited revenue for the fourth quarter of 2024, expected to be approximately $49.4 million. This represents a 15.1% increase over the fourth quarter of 2023, driven by solid commercial execution.
For the full year 2024, preliminary unaudited revenue is expected to be approximately $185.2 million. This figure indicates a 17.8% increase compared to the full-year 2023 revenue, demonstrating consistent growth.
These preliminary results highlight the company's continued expansion in the peripheral nerve repair market. The sustained double-digit growth underscores the effectiveness of Axogen's commercial strategies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.